检索历史 清除

随着对血管内皮生长因子(VEGF)在早产儿视网膜病变(ROP)发病机制中作用的研究不断深入。国内外陆续开展了各种抗VEGF药物1/2成人剂量玻璃体腔注射治疗ROP试验并初步取得显著疗效。然而，进一步的研究表明抗VEGF药物可以通过玻璃体腔进入全身血液循环，暂时降低患儿的血清VEGF水平，从而给处于快速生长发育期的早产儿带来潜在的全身不良反应。目前，国内外专家开始重点关注1/2成人剂量治疗ROP的全身不良反应风险，并相继开展了各种低剂量抗VEGF药物治疗ROP的相关研究。目前，大部分研究为小样本回顾性研究，缺乏大样本多中心的前瞻性研究，各剂量抗VEGF药物治疗ROP均属探索阶段。本文就各剂量抗VEGF药物治疗ROP的疗效及问题进行综述，为ROP的治疗提供参考。

With the further study of vascular endothelial growth factor (VEGF) in the pathogenesis of retinopathy of prematurity (ROP), a variety of anti-VEGF drugs with 1/2 adult dose have been used at home and abroad to treat ROP, and initially achieved remarkable curative effect.However, further studies have shown that anti-VEGF drugs can enter the systemic circulation through the vitreous cavity, which temporarily reduces serum VEGF levels in children.As a result, it may have potential systemic side effects for premature infants during the period of rapid growth and development.At present, experts at home and abroad have begun to pay attention to the risk of systemic side effects of ROP treated with 1/2 adult dose, and have conducted a variety of low-dose anti-VEGF drugs in the treatment of ROP.However, most of the studies are retrospective studies with small samples, and there is a lack of multicenter prospective studies with large samples.Therefore, all doses of anti-VEGF drugs in the treatment of ROP need to be further investigated.This article reviews the efficacy and problems of different doses of anti-VEGF drugs in the treatment of ROP to provide a reference for the treatment of ROP.